SCHEMBL5537816

SCHEMBL5537816

CC(C)(C)OC(=O)NC1CCC(CN2C(=O)c3ccccc3C2=O)C1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 8/20 0.55
KMT2A Q03164 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KDM1A O60341 1/20 0.47
MAOB P27338 1/20 0.47
BRD4 O60885 2/20 0.46
DRD3 P35462 1/20 0.44
KCNA3 P22001 1/20 0.42
EPHX2 P34913 1/20 0.42
BTK Q06187 1/20 0.41
SCN9A Q15858 1/20 0.41
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
CKS1B P61024 1/20 0.39
SKP1 P63208 1/20 0.39
SKP2 Q13309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5519650 1.00 DRD2 (0.55) DRD2KMT2AL3MBTL1KDM1AMAOB
SCHEMBL16524042 0.93 KMT2A (0.52) DRD2KMT2AL3MBTL1KDM1AMAOB
SCHEMBL7583988 0.93 DRD2 (0.60) DRD2KMT2AL3MBTL1KDM1AMAOB
SCHEMBL27504591 0.93 DRD2 (0.60) DRD2KMT2AL3MBTL1KDM1AMAOB
SCHEMBL8749508 0.84 DRD2 (0.51) DRD2KMT2AL3MBTL1KDM1AMAOB
SCHEMBL8749510 0.84 DRD2 (0.51) DRD2KMT2AL3MBTL1KDM1AMAOB
SCHEMBL8749514 0.84 DRD2 (0.51) DRD2KMT2AL3MBTL1KDM1AMAOB
SCHEMBL30772788 0.82 CYP2C9 (0.48) DRD2KMT2AL3MBTL1KDM1AMAOB
SCHEMBL19898547 0.82 CYP2C9 (0.48) DRD2KMT2AL3MBTL1KDM1AMAOB
SCHEMBL3897971 0.81 DRD2 (0.78) DRD2KMT2AL3MBTL1KDM1AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof MCHR1, GPR119, MCHR2 DRD2 54/4885KMT2A 792/4885L3MBTL1 3309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.